EP4727535A1 - Solriamfétol pour le traitement de certaines affections neurologiques - Google Patents

Solriamfétol pour le traitement de certaines affections neurologiques

Info

Publication number
EP4727535A1
EP4727535A1 EP24824369.3A EP24824369A EP4727535A1 EP 4727535 A1 EP4727535 A1 EP 4727535A1 EP 24824369 A EP24824369 A EP 24824369A EP 4727535 A1 EP4727535 A1 EP 4727535A1
Authority
EP
European Patent Office
Prior art keywords
solriamfetol
human
administered
day
total score
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24824369.3A
Other languages
German (de)
English (en)
Inventor
Herriot TABUTEAU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Axsome Therapeutics Inc
Original Assignee
Axsome Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axsome Therapeutics Inc filed Critical Axsome Therapeutics Inc
Publication of EP4727535A1 publication Critical patent/EP4727535A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des méthodes de traitement d'un trouble du déficit de l'attention avec ou sans hyperactivité (TDAH), d'un trouble dépressif majeur (TDM), d'un syndrome d'hyperphagie incontrôlée (BED), ou d'un trouble du au travail posté (SWD) chez les êtres humains, tels que chez les êtres humains adultes, par administration de solriamfétol à un être humain qui souffre de TDAH, de TDM, de BED ou de SWD. Le solriamfétol peut être administré le matin, par exemple dans l'heure qui suit le réveil. Dans certains modes de réalisation, le solriamfétol est administré plus de 9 heures avant l'heure prévue du coucher.
EP24824369.3A 2023-06-16 2024-06-17 Solriamfétol pour le traitement de certaines affections neurologiques Pending EP4727535A1 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202363508847P 2023-06-16 2023-06-16
US202363582340P 2023-09-13 2023-09-13
US202363588966P 2023-10-09 2023-10-09
US202363607505P 2023-12-07 2023-12-07
US202363607536P 2023-12-07 2023-12-07
PCT/US2024/034397 WO2024259446A1 (fr) 2023-06-16 2024-06-17 Solriamfétol pour le traitement de certaines affections neurologiques

Publications (1)

Publication Number Publication Date
EP4727535A1 true EP4727535A1 (fr) 2026-04-22

Family

ID=93852732

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24824369.3A Pending EP4727535A1 (fr) 2023-06-16 2024-06-17 Solriamfétol pour le traitement de certaines affections neurologiques

Country Status (4)

Country Link
EP (1) EP4727535A1 (fr)
KR (1) KR20260021022A (fr)
AU (1) AU2024304280A1 (fr)
WO (1) WO2024259446A1 (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012010670A2 (pt) * 2009-11-06 2016-04-12 Sk Biopharmaceuticals Co Ltd métodos para tratamento de distúrbio de défict de atenção/hiperatividade
WO2023235844A2 (fr) * 2022-06-03 2023-12-07 Axsome Therapeutics Composés de carbamoyl phénylalaninol utiles en tant qu'agonistes de taar1
WO2024145545A2 (fr) * 2022-12-30 2024-07-04 Axsome Malta Ltd. Procédés d'administration de solriamfétol à des femmes en lactation

Also Published As

Publication number Publication date
AU2024304280A1 (en) 2026-01-08
WO2024259446A1 (fr) 2024-12-19
KR20260021022A (ko) 2026-02-12

Similar Documents

Publication Publication Date Title
US12146889B1 (en) Compounds and combinations thereof for treating neurological and psychiatric conditions
US11844797B1 (en) Combination of dextromethorphan and bupropion for treating depression
US20250114349A1 (en) Combination of dextromethorphan and bupropion for treating depression
US20220226262A1 (en) Methods of treating doose syndrome using fenfluramine
Kahaly et al. Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial
Martin et al. Open-label quetiapine in the treatment of children and adolescents with autistic disorder
US20250177378A1 (en) Treatment of depression
Gruen et al. Efficacy and safety of an anti-nerve growth factor antibody (frunevetmab) for the treatment of degenerative joint disease-associated chronic pain in cats: a multisite pilot field study
Russell et al. Sodium oxybate reduces pain, fatigue, and sleep disturbance and improves functionality in fibromyalgia: results from a 14-week, randomized, double-blind, placebo-controlled study
Peer et al. Randomised crossover trial of naltrexone in uraemic pruritus
Kruszka et al. Clinical evaluation of the effects of a single oral dose of gabapentin on fear-based aggressive behaviors in cats during veterinary examinations
US20230149332A1 (en) Methods of treating seizure disorders and prader-willi syndrome
US20250188158A1 (en) Treatment of Parkinson's Disease
Ben-Menachem et al. Safety, tolerability, and efficacy of brivaracetam as adjunctive therapy in patients with focal seizures, generalized onset seizures, or Unverricht–Lundborg disease: an open-label, long-term follow-up trial
Silvestri et al. Pediatric restless legs syndrome
Greiner Clarifying the Confusion of Adult Emergence Delirium.
Kanai et al. Executive summary of the guideline for prescribing opioid analgesics for chronic non-cancer pain by the Japan Society of Pain Clinicians
WO2024259446A1 (fr) Solriamfétol pour le traitement de certaines affections neurologiques
Myrick et al. Clinical management of alcohol withdrawal
JP2010500377A (ja) 線維筋痛症に関わる認知機能障害を治療するためのミルナシプラン
JP2010500379A (ja) 線維筋痛症候群に関わる疲労を治療するためのミルナシプラン
WO2025064549A1 (fr) Solriamfétol pour améliorer la santé cognitive chez des patients sujets à l'apnée
Kordon et al. Exploring the impact of once-daily OROS® methylphenidate (MPH) on symptoms and quality of life in children and adolescents with ADHD transitioning from immediate-release MPH
US20250388647A1 (en) Therapies for mucopolysaccharidoses iii
Stolarb et al. Characteristics for Medical Cannabis Treatment Adherence among Autistic Children and Their Families: A Mixed-Methods Analysis

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251224

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR